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Abstract 
Neuronal pentraxins (NPTX) and their corresponding receptors (NPTXR) have been studied as 
synapse-associated proteins in the nervous system, but their role in cancer is largely unknown. 
By applying a multidisciplinary, high-throughput proteomic approach, we have recently identified a 
peptide ligand motif for targeted drug delivery to neuroblastoma. Here we report the sequence 
similarity between this peptide and a conserved portion of the pentraxin domain that is involved in 
the homo- and hetero-oligomerization of NPTX2 and NPTXR. We show that, in comparison to 
normal tissues, NPTX2 and NPTXR are overexpressed in vivo in mouse models, as well as in 
human Schwannian stroma-poor, stage IV neuroblastoma. Both proteins are concentrated in the 
vicinity of tumor blood vessels, with NPTXR also present on neuroblastic tumor cells. In vivo 
targeting of NPTX2 and NPTXR with the selected peptide or with specific antibodies reduces 
tumor burden in orthotopic mouse models of human neuroblastoma. In vitro interference with this 
ligand/receptor system inhibits the organization of neuroblastoma cells in tumor-like masses in 
close contact with vascular cells, as well as their adhesion to normal microenvironment-derived 
cells, suggesting a role in the crosstalk between tumor and normal cells in the early steps of 
neuroblastoma development. Finally, we show that NPTX2 is a marker of poor prognosis for 
neuroblastoma patients. 
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Introduction 
 Neuroblastoma (NB) is the most frequent solid malignancy in the first year of life. Despite 
recent improvements in treatment, the cure rate for patients with high-risk NB remains poor (1). 
The genetic nature of this disease has made it difficult to develop targeted therapies: only a few 
genes have been found mutated, and the occurrence of the corresponding genetic lesions is less 
than 10%, usually in the 1-3% range (2). Other potential targets have been identified by analysis 
of copy number variation and epigenetic modifications. However, most of these targets [MYCN, 
AURKA (3), CHD5 (4), ATRX (5), ARID1A/B (6), ODC (7)] are cytoplasmic or nuclear, making 
them challenging to target therapeutically. The transmembrane proteins ALK (8) and TrkB (9) are 
mutated or overexpressed in a substantial number of high-risk NB patients, representing 
potentially interesting targets. CD19 and GD2 membrane antigens (10) are being pursued for 
targeted radiation therapy and nanoparticle-driven drug delivery (11) as well as for antibody-
mediated immunotherapy (12), with some success in the treatment and prevention of NB. 
 While genetic and genomic analyses are powerful approaches for identifying potential 
therapeutic targets, they do not necessarily reflect the actual amounts, localization, and reciprocal 
interactions of the gene-encoded proteins. In addition, they provide data only on the tumor cells, 
without taking into account their microenvironment and tumor/normal tissue interactions, which 
play critical roles in tumorigenesis (13). Therefore, we have recently developed a multidisciplinary 
approach to investigate high-risk NB in the context of its native protein architecture, and 
characterized a set of specific peptide ligand motifs for NB-targeted drug delivery in vivo (14). 
 In the present work, we identify neuronal pentraxin-2 (NPTX2) and its receptor (NPTXR) 
as a functional ligand/receptor system in NB. Neuronal pentraxins were originally described in the 
brain as synapse-associated proteins (15), although they are expressed also in few other tissues. 
Their role as cancer-promoting agents is unknown, with a single recent report showing that 
NPTX2 is overexpressed in clear cell renal cell carcinoma and induces survival and migration of 
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tumor cells (16). Here we show that NPTX2 and NPTXR are upregulated in NB, and that 
blockage of the NPTX2 pathway inhibits the onset of NB by influencing the mutual recognition 
between tumor cells and their microenvironment. Finally, we propose the ligand NPTX2 as novel 
poor prognostic marker of human NB. 
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Materials and methods 
Peptides and antibodies. The previously described HSYWLRS (NB-targeting) and LAKALHA 
(control) sequences (14) were synthesized by the Institute of Chemistry of Molecular Recognition 
(National Council of Researches, Milan, Italy) with additional YSHS and GGG sequences at the 
N- and C-terminal, respectively, and a further C-terminal cysteine residue, resulting in the 
YSHSHSYWLRSGGGC (TARG) and YSHSLAKALHAGGGC (CTRL) peptide, respectively. The 
following antibodies were used for (i) in vivo studies: anti-NPTX2 (NBP1-50275, Novus 
Biologicals, Littleton, CO), anti-NPTXR (NPR/B-2, sc-390081, Santa Cruz Biotechnologies, Santa 
Cruz, CA); (ii) immunostaining: anti-NPTXR (NBP1-86531, Novus Biologicals; HPA001079, 
Sigma Aldrich, Saint Louis, MO, images in Fig. 1B, S2B and S2E), anti-NPTX2 (PRS4573, Sigma 
Aldrich), anti-CD146 (EPR3208, Millipore, Vimodrone, Italy), anti-ephrin A1 (sc-911, Santa Cruz 
Biotechnology), anti-integrin α11 (sc-98740, Santa Cruz Biotechnology); (iii) in vitro studies: anti-
NPTX2 (NBP1-50275), anti-NPTXR (NPR/B-2). 
Cell lines and human samples. The human NB-derived cell lines GI-LI-N, HTLA-230, SH-SY5Y 
and IMR-32 and umbilical vein endothelial cells (HUVECs) were cultured as described (14, 17). 
Human dermal microvascular endothelial cells (HMECs) were from LGC-Promochem (Sesto San 
Giovanni, Italy). Human brain vascular pericytes (HBVP) were from ScienCell Research 
Laboratories (Carlsbad, CA). To obtain fluorescent cells for the in vitro assays, GI-LI-N, HTLA-
230 and SH-SY5Y cell lines were stably transfected with a plasmid expressing the enhanced 
green fluorescent protein (pCMS-EGFP, Clontech, Mountain View, CA). Cells were tested and 
proven negative for mycoplasma contamination and characterized by proliferation, morphology 
evaluation, and multiplex short tandem repeat profiling. Snap-frozen samples of Schwannian 
stroma-poor, stage IV NB were provided by BIT. Collection and manipulation of human samples 
were approved by the Institutional Review Board (IRB). Informed written consent was obtained 
from each patient in accordance with the Declaration of Helsinki. 
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Mouse models. Athymic (nu/nu) female mice were purchased from Harlan Laboratories (Harlan 
Italy, S. Pietro al Natisone, Italy) and housed under pathogen-free conditions. Experiments were 
approved by the Institute Animal Care and Use Committee (IACUC, IRCCS University Hospital 
San Martino - National Institute for Cancer Research, Genoa, Italy) and by the Italian Ministry of 
Health. For the orthotopic models, 5-week-old mice were injected into the left adrenal gland with 
106 NB cells; for the pseudo-metastatic models, 4-week-old mice were injected into the tail vein 
with 4 × 106 NB cells, as described (14). To evaluate the effect of NPTX2 and NPTXR targeting, 
GI-LI-N or IMR-32 cells were mixed with CTRL or TARG (100 µM), or with anti-NPTX2 or anti-
NPTXR antibody (5 µg/animal) immediately before orthotopic implantation. One month after tumor 
challenge, mice were killed and tumors explanted. 
Data Analysis. Statistical analyses were performed with Prism 5 software (GraphPad, La Jolla, 
CA). Depending on sample numbers, t-test or Fisher's exact test (two-tailed) were used to 
compare selected experimental points. Correlation between NPTXR, NPTX2 and VE-cadherin 
expression with patient outcome was explored using the "R2: microarray analysis and 
visualization platform" (http://r2.amc.nl) with default parameters for Kaplan-Meier survival graphs. 
The analysis was performed on the SEQC (SEquencing Quality Control) neuroblastoma project 
dataset, and the significance was evaluated by Chi-square test. 
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Results and Discussion 
 We have recently isolated a peptide motif as specific ligand for mouse models of human 
NB (14). To identify corresponding native ligands, we performed a BLAST analysis against the 
human and mouse proteomes. Four transmembrane or secreted proteins were retrieved with high 
homology scores. Of these, ephrin-A1 and α11 integrin were not further studied because their 
expression was barely detectable in NB tissues, as evaluated by IF staining followed by confocal 
microscopy and quantification (Fig. S1, fluorescent pixels × 106). On the other hand, NPTX2 and 
NPTXR were detected in samples from a panel (n=9) of tumor models obtained by either 
orthotopic or i.v. injection of NB cell lines (i.e., GI-LI-N, HTLA-230, SH-SY5Y, IMR-32) in athymic 
mice (Fig. 1A, fluorescent pixels × 108; Fig. S2A, overview of the quantified images; Fig. S2B, 
controls). IF staining of tumor xenografts showed a non-homogeneous localization for these 
proteins (Fig. 1B) and, in association with a detailed morphological analysis by IHC, revealed 
that, while NPTX2 expression is confined to blood vessel-forming and/or surrounding cells (Fig. 
1C, black arrows), NPTXR is present in high amounts also in neuroblastic cells (Fig. 1C, red 
arrows). These data are consistent with the in vitro expression levels of NPTX2 (low) and NPTXR 
(medium) in these same NB cell lines, as evaluated by flow cytometry (Fig. S2C) and confirmed 
by immunoblot (Fig. S2D). Non-tumor tissues (kidney, adrenal gland, liver) from control animals 
were largely negative for NPTX2 and NPTXR expression (Fig. S3). These findings suggest that 
the onset and/or progression of NB induce the expression of both ligand and receptor in normal 
cells of tumor microenvironment, with a concomitant upregulation of the receptor in tumor cells. 
 NPTX2 and NPTXR represent a peculiar ligand/receptor system whose components share 
~50% identity in the overall sequence, and 64% identity in the pentraxin domain where the 
homology with the targeting peptide is present. Because this domain is responsible for protein-
protein interactions leading to functional homo- and hetero-oligomerization (18), we hypothesized 
that a targeted disruption of such interactions might impact on NB development. To investigate 
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this hypothesis, we first used two mouse models obtained by orthotopic implantation of GI-LI-N 
and IMR-32 cells into the adrenal glands. We injected cells alone or in the presence of either 
control (CTRL) or NB-targeting (TARG) peptide, or in the presence of either anti-NPTX2 or anti-
NPTXR antibody. After 30 days, mice were killed and organs recovered for tumor burden 
analysis. We observed a reduction in tumor volume in mice receiving NB cells in the presence of 
the targeting peptide, as well as of the specific antibodies, compared to cells alone (not shown) or 
cells plus control peptide (Fig. 1D). This reduction was significant for all the experimental points in 
the GI-LI-N model, and for the anti-NPTXR experimental point in the IMR-32 model. A higher 
affinity/blocking efficiency of the anti-NPTXR monoclonal antibody in comparison to both the 
peptide and the polyclonal anti-NPTX2 antibody, coupled with slightly different expression levels 
of the targets, might account for the different significance observed. After treatments, the overall 
amounts and distribution of both proteins, as well as the vascular architecture, were maintained 
(Fig. 1E), suggesting that interference with NPTX2 and NPTXR possibly affects early steps of 
tumor/normal tissue reciprocal recognition, rather than influencing successive tissue organization 
during tumor progression. 
 We therefore evaluated whether in vitro blockage of NPTX2 and/or NPTXR would impact 
the interaction of NB cells with normal cells from the tumor microenvironment. In a first set of 
experiments, we prepared mixed co-cultures of fluorescently labeled NB cells (GI-LI-N, HTLA-
230, SH-SY5Y) and endothelial cells (HUVECs), and grew them in the presence of either CTRL, 
TARG, anti-NPTX2 or anti-NPTXR. The mixed cells globally reached confluence at the same time 
in all the experimental conditions; however, their distribution was influenced by the presence of 
NB-targeting peptide and antibodies. Under control conditions, NB cells were organized in large 
aggregates reminiscent of tumor masses. In contrast, NPTX2/NPTXR-targeting conditions caused 
NB cells to become sparse or organized in small clusters. Quantification of highly fluorescent 
areas (NB cell aggregates) confirmed this redistribution was significant for almost all the 
experimental points (Fig. 2A). We investigated whether this effect was related to NPTX2/NPTXR-
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mediated cell-cell binding, by incubating each fluorescent NB cell line on confluent layers of 
macrovascular (HUVECs), microvascular (HMECs) or perivascular (HBPV) cells, in either control 
or NPTX2/NPTXR targeting conditions. Adhesion of NB cells onto macrovascular and 
microvascular cells was impaired when NPTX2 and NPTXR were targeted; binding to 
perivascular cells was only slightly affected by interference with the NPTX2/NPTXR pathway (Fig. 
2B). All these microenvironment cells express both NPTX2 and NPTXR; however, NPTXR levels 
are markedly higher in pericytes (Fig. S2D-E), possibly accounting for the weaker inhibition 
observed. We also evaluated whether NPTX2 and/or NPTXR had a role in NB cell migration 
towards normal microenvironment cells. For these assays, we chose the SH-SY5Y cell line after 
extensive characterization of the migratory properties in all NB cell lines (Fig. S4). Interestingly, 
attraction of SH-SY5Y was increased by treatment with either targeting peptide or anti-NPTXR 
antibody, while interfering with NPTX2 was ineffective (Fig. 2C). Together, these data show that 
NPTX2 and NPTXR affect the spatial organization and reciprocal recognition of neuroblasts and 
normal cells. They demonstrate that, in this setting, (i) the NPTX2/NPTXR pathway has a pro-
adhesive effect, (ii) NPTXR, possibly activated by an alternative ligand such as NPTX1 (18), has 
an anti-migratory effect, and (iii) both functions are reverted by a specific targeting of NPTX2 
and/or NPTXR. 
 Having shown that NPTX2 and NPTXR are potential targets in NB in vivo and in vitro, we 
evaluated their expression in human NB samples. The overall tissue distribution of both proteins 
was similar to that seen in the mouse models, although more background was visible in the 
staining for NPTX2, due to technical issues (FFPE mouse samples versus snap-frozen human 
specimens) (Fig. 3A). Notably, in contrast to the high amounts of both NPTX2 and NPTXR 
detected in NB, undetectable to low expression of these proteins is reported by the Human 
Protein Atlas (19) for the same normal tissues that we evaluated in mice (Fig. S5). These data 
demonstrate that both proteins are overexpressed in NB in clinical settings. 
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 This finding led us to investigate a possible involvement for either protein during the 
progression of human NB. For this purpose, we exploited public microarray expression data that 
we evaluated through the "R2 microarray analysis and visualization platform". Analysis of a large 
patient dataset (SEQC, n=498) revealed that high levels of NPTX2 strongly correlated with poor 
overall survival (P = 3.2e-06). Unexpectedly, NPTXR had a different trend, although with lower 
significance (P = 0.019) (Fig. 3B). One might speculate a possible explanation for this paradoxical 
result is that, while NPTX2 localizes prevalently to vascular compartments, NPTXR is expressed 
also by tumor cells distant from the blood vessels (Fig. 1C and E). It is therefore conceivable that 
a substantial amount of the receptor binds to an alternative pentraxin ligand (18, 20), with a 
different biological outcome. Unfortunately, the SEQC dataset reports only a whole-tissue mRNA 
expression analysis, from which it is impossible to distinguish among the different species of 
NPTXR. The poor prognostic value of NPTX2 was not a surrogate for endothelial cell content: 
another endothelial expressed gene, VE-cadherin followed an opposite trend and correlated with 
good overall survival (P = 6.1e-05) (Fig. 3B). 
 In conclusion, we show that NPTX2 and NPTXR mediate tumor/normal cell recognition in 
NB and that interfering with this ligand/receptor system is a potential approach towards the 
development of an innovative targeted therapy. We summarize the proposed mechanism in Fig. 
4. Finally, we show that NPTX2 is a novel poor prognosis tumor marker for NB patients. 
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Figure Legends 
Figure 1. NPTX2 and NPTXR are functional markers in experimental mouse models of NB. 
NPTX2 and NPTXR were evaluated by IF and IHC in the following tumor samples: G1-2, 
orthotopic GI-LI-N cells (G1, primary tumor; G2, lymph node metastasis); H1-4, i.v. HTLA-230 
cells (tumor mass in: H1, left ovary; H2, right kidney; H3, right adrenal gland; H4, left adrenal 
gland); S1, orthotopic SH-SY5Y cells, primary tumor; I1-2, i.v. IMR-32 cells (tumor mass in: I1, 
bladder; I2, right adrenal gland). FFPE tissues were immunostained for NPTX2 and NPTXR. (A) 
Quantification of specific signals by ImageJ; graph bars represent mean ± S.D. from 6 pictures of 
each sample. (B) Representative IF pictures. Anti-NPTXR, HPA001079; nuclei, DAPI. (C) Subset 
of NB tissues IHC-stained and counterstained with hematoxylin. Black arrows, blood vessels; red 
arrows, tumor cells. (D-E) GI-LI-N or IMR-32 cells were implanted into the adrenal gland (n=5 
mice per group) in the presence of CTRL, TARG, anti-NPTX2 or anti-NPTXR. Tumor volumes 
were evaluated after 30 days (D). Representative IHC staining of samples from the GI-LI-N 
model; arrows as in Fig. 1C (E). The experiment was performed twice with similar results. 
*, P< 0.05; ***, P< 0.001 
Figure 2. NTPX2 and NPTXR drive the mutual interaction between NB and 
microenvironment cells. (A) Fluorescent NB cells were mixed with HUVECs and grown to 
confluence in the presence of CTRL or NPTX2/NPTXR-targeting agents. Fluorescent areas were 
quantified with ImageJ and have been processed in reverse-mode to be visualized in black. NB 
cells were evaluated for their adhesion on confluent layers of HUVECs, HMECs or HBPV cells in 
the same conditions as in A; adhered cells were counted with ImageJ (B). Migration of SH-SY5Y 
cells towards HUVECs, HMECs or HBPV cells (5 × 104/well) was evaluated in a transwell system 
in the same conditions as in A; migrated cells were stained with crystal violet and counted under 
a light microscope (C). Graph bars represent mean ± S.D. from triplicate points of two 
independent experiments. 
*, P< 0.05; **, P< 0.01; ***, P< 0.001 
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Figure 3. NPTX2 and NPTXR are expressed in human NB, where NPTX2 is a prognostic 
marker of poor outcome. IF and IHC staining of human specimens were performed as 
described in Fig. 1. Patient IDs: Patient #1, 07-B-1173 A1; Patient #2, 07-B-1312 A2; Patient #3, 
07-B-1617 A2. Representative tissue staining is shown. White arrows, blood vessels; red arrows, 
tumor cells (A). The correlation between NPTX2, NPTXR and VE-cadherin expression and 
clinical outcomes in NB patients was evaluated on the SEQC dataset (B). 
Χ2 = 21.70; P = 3.2 × 10-6 (NPTX2); Χ2 = 5.48; P = 0.019 (NPTXR); Χ2 = 16.07; P = 6.1e-05 (VE-
cadherin) 
Figure 4. The targeting of NPTX2 and NPTXR inhibits NB. A highly conserved pentraxin 
domain is present in both NPTX2 and NPTXR, mediating homo- and hetero-oligomerization 
(likely, pentamerization) of these proteins. The NPTX2/NPTXR pathway is responsible for the 
reciprocal recognition between normal microenvironment cells and neuroblasts that promotes NB 
onset and progression. In the presence of a targeting agent, such as the TARG peptide, these 
interactions are disrupted, resulting in the inhibition of tumor onset and progression. 
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